Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership

SPRUCE BIOSCIENCES, INC.

2023-Q2 EPS reported -$1.01

Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.
Cash, equivalents and investments $99.1M as of June 30, 2022.
CAHmelia-203 surpassed 25% enrollment; CAHmelia-204 approaching 25% enrollment.
Appointed P.J. Ramtin as SVP of Business Operations; two new tildacerfont method-of-use patents issued, exclusivity through 2038.
Abstract on Phase 2a CAH data accepted for oral presentation at ICE 2022 (Aug 27).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.